Format

Send to

Choose Destination
Front Oncol. 2018 Apr 4;8:95. doi: 10.3389/fonc.2018.00095. eCollection 2018.

CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma.

Author information

1
Yale School of Medicine, New Haven, CT, United States.
2
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, United States.
3
Yale Cancer Center, Yale School of Medicine, New Haven, CT, United States.
4
University of Connecticut School of Medicine, Farmington, CT, United States.
5
Department of Biostatistics, Yale School of Public Health, New Haven, CT, United States.
6
Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Yale School of Medicine, New Haven, CT, United States.

Abstract

Background:

HPV infection is associated with high p16 expression and good prognosis in head and neck squamous cell carcinomas (HNSCCs). Analysis of CDKN2A, the gene encoding p16, may further elucidate the association between p16 expression and prognosis. We sought to determine whether CDKN2A copy number loss was associated with poor survival in HPV-negative HNSCCs.

Methods:

The Cancer Genome Atlas HNSCC clinical and genomic data were obtained and integrated. Patients <80 years old with a primary tumor in the oral cavity, oropharynx, hypopharynx, or larynx were included. Stratifying by copy number loss status, CDKN2A mRNA and p16 protein expression levels were examined and overall survival (OS) and disease-free survival (DFS) were evaluated.

Results:

401 patients with HPV-negative HNSCC were identified. 146 patients demonstrated CDKN2A copy number loss. The CDKN2A copy number loss group expressed significantly lower levels of CDKN2A mRNA and p16 protein than did the non-copy number loss group. Median OS for patients with and without CDKN2A copy number loss was 16.5 and 46.6 months, respectively (p = 0.007). Median DFS for both groups was 11.6 and 19.2 months, respectively (p = 0.03). In both univariate and multivariable analyses, stage IV designation, receipt of chemotherapy and CDKN2A copy number loss were predictive of OS.

Conclusion:

CDKN2A copy number loss predicted poor survival independently of other patient and treatment factors and may be a clinically useful prognostic factor.

KEYWORDS:

CDKN2A; genomics and genetics; head and neck neoplasms; outcomes assessment; prognostic biomarkers

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center